MedPath

study of addition of tramadol(analgesic) to ropivacaine(local anaesthetic) for wound infiltration in spine surgeries on postoperative pain relief

Not yet recruiting
Conditions
•All patients belonging to American society of Anesthesiologists physical status grade I and II •Age between 18 to 60 years.
Registration Number
CTRI/2016/08/007201
Lead Sponsor
Sri Venkateswara Institute of Medical Sciences
Brief Summary

Wound infiltration by local anaesthetics has become increasinglycommon for postoperative analgesia owing to its simplicity, safety andeffectiveness and its provision of effective postoperative analgesia, particularlyafter surgical procedures. TramadolHydrochloride is a synthetic analogue of codeine when added as an adjuvant tolocal anaesthetic agents, causes an effect similar to that of clonidine and itcan modify the effects of local anaesthetics by directly or indirectlyeffecting sodium channels, thus contributing to more effective analgesia. Combinationof ropivacaine and tramadol for wound infiltration after spine surgeries mayprovide superior analgesic effects compared with the sole administration of ropivacainethrough the same route. However the optimum dose of tramadol as an adjuvant hasnot been defined conclusively. The present study is aim to assess the analgesicefficacy of two different doses of tramadol added to ropivacaine for woundinfiltration in spine surgeries.

Patients will be randomized to receive their study drugs after thespinal surgery and before closing the incision line .The study drug as pergroup allocation will be injected over the incision line on the paravertebralmuscles, cutaneous and subcutaneous tissue with equal volume on either sides.This will be followed by reversal of residual neuro-muscular block and aftermeeting extubation criteria patient will be extubated and shifted to recoveryroom.

Post operatively pulse rate , blood pressure, respiratory rate, oxygensaturation , numerical rating score(NRS), sedation score will be monitoredevery hourly till the patient complains of pain or NRS > or equal to 4.Level of sedation will be assessed by Ramsay sedation score.

Time to first analgesic requirement will be the time since woundinfiltration done to the time when the patient complains of pain or NRS > orequal to 4. At that time patients will be administered additional analgesiawith inj fentanyl 1mcg/kg IV. Postoperatively all patients will be given injparacetamol 15mg/kg IV every 6th hourly.

Post operatively patients will be monitored for adversecardiovascular and respiratory event, nausea, vomiting and any other sideeffects will be noted within 24 hours.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
90
Inclusion Criteria

1)All patients belonging to American society of Anesthesiologists physical status grade I and II 2)Age between 18 to 60 years.

Exclusion Criteria
  • 1)Allergy to any of study drugs.
  • 2)Patients on treatment with chronic opioids or study drugs.
  • 3)Who have cardiovascular, pulmonary, renal, neurological and metabolic diseases.
  • 4)Inability to comprehend numerical rating scale.
  • 5)Who undergo cervical spine surgeries.
  • 7)Pregnant and lactating mothers.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary outcome variable will be determined as the time to first analgesic administration by recording numerical rating scale every hour postoperatively after infiltration of the study drug.Time frame 24 hours after surgery
Secondary Outcome Measures
NameTimeMethod
Any adverse effects observed with ropivacaine and tramadol will be determined as secondary outcomeTime frame 24 hours after surgery

Trial Locations

Locations (1)

Sri Venkateswara Institute of Medical Sciences

🇮🇳

Chittoor, ANDHRA PRADESH, India

Sri Venkateswara Institute of Medical Sciences
🇮🇳Chittoor, ANDHRA PRADESH, India
Dr Aloka Samantaray
Principal investigator
9493547653
aloksvims@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.